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September 2021or sacral radicular arteries, when the Adamkiewicz artery
originates abnormally high or is chronically occluded.3
The variable intensity of sensorimotor deficits might be
explained by the variable collateralization of the spinal
arterial supply.4 However, urgent revascularization is al-
ways required for both causes. The neurologic recovery
will be better in the case of peripheral ischemia.
However, patients can also have spinal cord compres-
sion with no relationship to COVID-19 infection. The pres-
ence of COVID-19 infection can lead us astray, and we
can miss the urgent diagnosis requiring medullar mag-
netic resonance imaging studies and surgical decom-
pression.5 Finally, the diagnosis might be acute
myelopathy associated with COVID-19 infection6; howev-
er, this must remain a diagnosis of elimination, in partic-
ular, because no specific treatment is available. Thus,
with or without COVID-19 infection, patient with acute
paraplegia must very quickly undergo computed tomog-
raphy and, if the findings are negative, medullar mag-
netic resonance imaging.
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Deepening immunoinflammatory featuresIt was the end of 2019 when severe acute respiratory syn-
drome coronavirus-2, the respiratory pathogen capable of
binding to human angiotensin-converting enzyme 2 re-
ceptors and responsible for coronavirus disease 2019
(COVID-19), was isolated in Wuhan, China; since then,
COVID-19 has been affecting the worldwide population
for its many clinicopathologic aspects, including vasculo-
coagulative ones.1,2 The interesting study by Indes et al1
correlates the high incidence of arterial thromboembolic
events with COVID-19 severity, outlining, as key factors,
an abnormal immune/inflammatory reaction, and a
hypercoagulative state.1 Deepening their pathophysio-
logic features helps to better understand this
complication.
The lymphocytic endotheliitis, which is expressed early
with endothelial cells damage, and a consequent accel-
erated pyroptosis can evolve toward a leukocytoclastic
vasculitis, a frank acute necrotizing vasculitis owing to
immune complexes and complement fraction deposi-
tions as well as activation in the vascular walls, character-
ized by the infiltration of neutrophils into the media and
adventitial layers of small and medium arteries and the
occurrence of fibrinoid necrosis.3,4 This diffuse endothe-
lial damage is followed by an increase in the circulating
endothelial cells and a type III hypersensitive reaction.4,5
The severity of COVID-19 includes a progressively higher
production of cytokines, inducing, among other compli-
cations, a hypercoagulative state. In particular, IL-6 corre-
lates with an augmented megakaryocytopoiesis, proven
by histologic study of bone marrow and lungs with a
high number of denuded megakaryocytes.6 This is fol-
lowed by a greater release of circulating platelets, already
active in the earlier stages of this disease in repairing
damaged vascular endothelia, and, according to their
myeloid origin, in performing covercytosis against virions.6
In the meantime, from an immunologic perspective, a
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Volume 74, Number 3secondary antiphospholipid immune syndrome may
develop with the production of autoantibodies, such as
lupus anticoagulant, anticardiolipin, and anti-b2-glycopro-
tein-I.7 Their binding to the membrane phospholipids of
platelets and vascular endothelia cells takes part in gener-
ating thrombi and inflammatory cells aggregates of
different sizes. This abnormal immunothrombosis involves
the microvessels and medium or large arteries, causing
complete or mural thromboses, respectively.
Predisposing factors include endothelial dysfunction or
local turbulent blood flow secondary to severe atheroscle-
rosis, vascular prosthesis, or endografts.7 Moreover, the his-
tologic characteristics of COVID-19 are hyperimmune,
rather than a common inflammatory pathology, and
correlate, in larger arteries, with the absence of secondary
intramural hematomas, dissections, and mainly inflam-
matory aneurysms, notwithstanding the thrombosis that
affects in the big arteries the vasa vasorum.7 We think
that this cascade of pathologic events will be further eluci-
dated when the impact of the host humoral response on
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https://doi.org/10.1016/j.jvs.2021.04.060ReplyWe would like to thank Roncati et al for their letter
and comments related to our article. Approximately
1 year ago in the early stages of the coronavirus disease
2019 (COVID-19) pandemic, hospitals in New York City
experienced some of the highest concentrations of
cases in the United States. We cared for a great number
of patients with arterial and/or venous thromboembolic
complications related to severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) infection. Among
these were many patients with COVID-19 and acute
arterial ischemia requiring emergent surgical
treatment.
In addition to the greater mortality, we found these
patients had a higher body mass index, higher average
in-hospital D-dimer levels, and lower rates of antiplate-
let usage. This constellation suggested that a general-
ized hyperinflammatory, hypercoagulable state, as
nicely outlined in detail by Roncati et al in their letter
to the editor, was primarily responsible. Finally, we
found an unusual preponderance of large vessel throm-
boses, including those in the aortoiliac distribution. Dur-
ing the past year, the hypercoagulability seen in
patients with COVID-19 has been increasingly eluci-
dated and will continue to be further characterized.
Although this has been an extremely difficult time for
healthcare workers around the world, the opportunity
for cross-specialty and global collaboration, as is illus-
trated by their letter to the editor and our article in
the Journal, has been rewarding and hopefully will
help expedite the characterization of these processes
at a more detailed cellular and molecular level.
As we continue to treat patients with SARS-CoV-2
infection, we expect to encounter new and challenging
obstacles such as the arterial and venous complications
described. For example, we have seen in recent weeks
the characterization of an even newer phenomenon, a
condition known as SARS-CoV-2 vaccineeinduced im-
mune thrombotic thrombocytopenia. As was recently
demonstrated in a New England Journal article, the
mechanism of this hypercoagulable disorder related
to COVID-19 vaccination is closely related to that which
leads to heparin-induced thrombocytopenia.1 This re-
quires treatment with noneheparin anticoagulant
agents. It is important to differentiate hypercoagulable
complications such as these in patients with SAR-CoV-
2 infection because the treatment implications could
